Advanced lung cancer

The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...


The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...


The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...


The results of a study has shown that patients living with HIV and one of a variety of potentially deadly...


Neoadjuvant, or pre-surgical, treatment with Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) resulted in an overall major pathologic...


Early data from two clinical trials have shown reduced survival with Keytruda ( Pembrolizumab ) and Tecentriq ( Atezolizumab )...


The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...


Alectinib ( Alecensa ) has proven systemic and CNS efficacy in patients with ALK+ aNSCLC ( advanced non-small cell lung...


Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ...


CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab...


CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy...


The phase 2 ATLANTIC study has investigated the anti-PD-L1 antibody Durvalumab ( Imfinzi ) in heavily pretreated patients with advanced...


The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...


The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and...


The Food and Drug Administration ( FDA ) has approved Osimertinib ( Tagrisso ) for the first-line treatment of patients...


Treatment with Nazartinib ( EGF816 ), a third generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (...


The FDA ( U.S. Food and Drug Administration ) has approved Larotrectinib ( Vitrakvi ), the first oral TRK inhibitor. The...